FDA Advisory Committee Votes in Favor of WAYLIVRA for Treatment of Familial Chylomicronemia Syndrome

Advisory Committee members vote 12-8 to support approval CAMBRIDGE, Mass. and CARLSBAD, Calif., May 10, 2018 (GLOBE NEWSWIRE) — Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that the U.S. Food and Drug Administration’s (FDA) Division of Metabolism and Endocrinology Products

Akcea Announces Expansion of Global Early Access Program to Provide Volanesorsen to People Living with FCS

Program currently available in the U.S. and select countries in Europe; initiating additional countries throughout 2018 CAMBRIDGE, Mass., May 02, 2018 (GLOBE NEWSWIRE) — Akcea Therapeutics, Inc.(NASDAQ:AKCA) today announced it has expanded its global early access program (EAP) to the United States for people with

Akcea Therapeutics Announces Presentations on Volanesorsen and FCS at the National Lipid Association Scientific Sessions

Results to be presented show significant reduction in triglyceride levels associated with reductions of pancreatitis and burden of disease in patients with FCS CAMBRIDGE, Mass. and LAS VEGAS, April 26, 2018 (GLOBE NEWSWIRE) — Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing